ParagonDx, LLC (ParagonDx) has appointed Jorge Leon to its scientific advisory board. Leon has more than 20 years of experience as an industry leader in molecular diagnostics. Leon has evaluated, developed and commercialized new technologies and scientific innovations into successful diagnostic products. As one of the founders of the molecular diagnostics and applied genomics business at Quest Diagnostics (Quest), Leon spent 12 years developing the Quest’s molecular diagnostic strategy.
In his role at Quest, Leon held several positions over time, including director of molecular diagnostics, senior director of biotechnology department, and vice president of applied genomics.
“We are extremely pleased to have Dr. Leon join our scientific advisory board,” says Michael Murphy, president and chief executive officer of ParagonDx. “Given Dr. Leon’s background in molecular diagnostics, his guidance will significantly advance the company’s position within the diagnostic industry.”
Leon received his PhD in Cellular and Molecular Biology from New York University and completed postdoctoral studies at German Cancer Research Center in Heidelberg and Columbia University. He performed academic research on developing monoclonal antibody-based tumor marker assays and radio-immuno imaging devices, which are widely used today.
Leon founded Leomics Associates, Inc., in 2003, a consulting firm which specializes in identifying breakthrough opportunities and industry trends, and helping start-ups, academic centers and established companies build and commercialize innovative business strategies, product pipelines and test menus.
Leon holds several patents, has been published extensively and serves on board of various leading edge technology companies.
“I am pleased to be associated with ParagonDx and their innovative approach to personalized medicine,” says Leon. “It is exciting to be working with a leading edge company creating high quality molecular diagnostic products and services targeted at saving lives.”